Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 15;7(4):973-81.
eCollection 2014.

Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer

Li-Xia Zeng  1 , Yong Tang  2 , Yun Ma  1
Affiliations

Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer

Li-Xia Zeng et al. Int J Clin Exp Med. .

Abstract

To investigate the expression of Ataxin-3 in human gastric cancer tissues and cell lines, and explore its clinical pathologic significance.

Methods: The expression of Ataxin-3 in gastric cancer (n=536) and noncancerous gastric mucosa (n=312) was determined by immunohistochemistry and correlated to clinicopathologic features such as histologic differentiation and tumor size. The expression of Ataxin-3 protein in the human gastric cancer cell lines MKN45, SGC7901 and in normal human gastric epithelial cells (GES-1) was also evaluated by Western blot analysis. Quantitative real-time PCR was used to determine Ataxin-3 mRNA expression in human gastric cancer cell lines and tissues.

Results: The expression of Ataxin-3 protein was decreased in the gastric cancer compared to noncancerous gastric tissue, and correlated with tumor size, Lauren classification, histologic differentiation, and mutant p53 protein (P < 0.05). Similarly, Ataxin-3 mRNA expression was decreased in the gastric cancers compared to the noncancerous gastric tissue. Ataxin-3 protein and mRNA expression was lower in MKN45, SGC7901 cells than in the normal GES-1 cells.

Conclusion: Decreased expression of Ataxin-3 may play an important role in gastric carcinogenesis and development of gastric cancer.

Keywords: Ataxin-3; clinicopathologic features; gastric cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of Ataxin-3 protein in human gastric cancer and noncancerous tissues. A: Representative tissue section showing moderate immunoreactivity (++) in GC tissue. B: An example of weak immunoreactivity (+) in GC tissue. C: An example of a GC tumor with negative immunoreactivity (-). D: Noncancerous gastric mucosa exhibiting strong Ataxin-3 immunoreactivity (+++). (All slides ×200 magnification).
Figure 2
Figure 2
Western blot analysis of Ataxin-3 protein expression in human GC cell lines (MKN45 and SGC7901) and human normal gastric epithelial cells (GES-1). Ataxin-3 protein expression was highest in the GES-1 cells and higher in SGC7901 than MKN45.
Figure 3
Figure 3
Quantitative RT-PCR analysis of Ataxin-3 mRNA expression. Ataxin-3 mRNA expression was lower in gastric cancer tissues and gastric cancer cell lines than in the control noncancerous gastric tissues and cell line. A: Expression of Ataxin-3 mRNA in human tissue samples (GC - n = 14; noncancerous gastric mucosa - n = 14; Standard Error of the Mean (SEM), experiment performed in triplicate; Ataxin-3 mRNA expression relative to GAPDH). B: Expression of Ataxin-3 mRNA in human GC cell lines (MKN45 and SGC7901) and in normal gastric epithelial cells (GES-1).
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
    1. Shin HR, Carlos MC, Varghese C. Cancer control in the Asia Pacific region: current status and concerns. Jpn $lxfS1$ 2012;42:867–881. - PubMed
    1. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21. - PMC - PubMed
    1. Thun M, Jemal A, Desantis C, Blackard B, Ward E. An overview of the cancer burden for primary care physicians. Prim Care. 2009;36:439–454. - PubMed
    1. Shen M, Schmitt S, Buac D, Dou QP. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets. 2013;17:1091–1108. - PMC - PubMed